Conclusion
the dossier summarised in one paragraphThe computed 12-month bankruptcy probability of EYED PHARMA is 0.3% (very low). The company has been active since 2012 and the Belgian State Gazette contains no insolvency or warning signals. No processed annual-account figures are available; this conclusion rests on registry and State Gazette data only.
Based on State Gazette and CBE data.
Financials
No processed annual-account figures available.
To financials
People & board
16 mandates
13
active directors
Jean-Philippe COMBALDirectorNOSHAQ SADirectorPierre BELICHARDDirector+13 in history
All directors & mandates Publicationslatest 28-04-2026
67
publications in the State GazetteCapital decrease of €12,975,077.13 to €11,872,836.37All publications & acts Network & structure
38
connected companiesSee network & structure
Connections
38 connected companiesParent · 3 subsidiaries · 1 location
Control→
Parent · 26 subsidiaries · 2 locations
Control→
Parent · 11 subsidiaries · 2 locations
Control→
Trust signals
3 signalsEstablished
Founded in 2012 — 13 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad.
Administratively compliant
No FOD Economie strikeouts (UBO, accounts, address, activity).
Administrative Flags
0 events
No administrative flags
Bankruptcy probability (12 mo)
Checked model v1 · free for everyone0.3%
Very low
0%0,5%1,5%4%10%≥25%
Lower-failure-rate sector
−Lower-risk legal form
−Long track record
−
Statistical estimate based on public sources — not credit advice nor a finding of fact. How do we compute this?
Company registry (CBE)
Crossroads BankActivities
Speur- en ontwikkelingswerk op biotechnologisch gebied72101Speur- en ontwikkelingswerk op biotechnologisch gebied72110
Primary activity highlighted.
Names & trade names
| Legal nameFR | EYED PHARMA |
Registered office
Rue Louis Plescia 9
4102 Seraing, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.